Ceftazidime/avibactam alone or in combination with an aminoglycoside for treatment of carbapenem-resistant Enterobacterales infections: A retrospective cohort study
In veterans treated with ceftazidime/avibactam for CRE infections, increased age, receipt of an empiric aminoglycoside, and presence in the ICU at the time of index culture were associated with higher 30-day mortality. Among patients who received an aminoglycoside, their use in combination with ceftazidime/avibactam trended toward protectiveness of 30-day mortality, suggesting a potential role for this combination to treat CRE infections in patients who are more severely ill.
Authors
- Katie J. Suda
- Mark Biagi (ORCID: https://orcid.org/0000-0001-5190-0066)
- Charlesnika Tyon Evans (ORCID: https://orcid.org/0000-0002-0696-8288)
- Zackery P. Bulman (ORCID: https://orcid.org/0000-0002-5396-911X)
- Lishan Cao
- Amanda Vivo (ORCID: https://orcid.org/0000-0002-8950-527X)
- Brooke N Curry
Institutions
- Illinois College (US)
- Edward Hines, Jr. VA Hospital (US)
- University of Illinois Chicago (US)
- VA Pittsburgh Healthcare System (US)
Publication Details
- Journal
- International Journal of Antimicrobial Agents
- Published
- 2024-09-05
- DOI
- https://doi.org/10.1016/j.ijantimicag.2024.107321
- Citations
- 5
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- U.S. Department of Veterans Affairs
- Office of Research and Development
- Health Services Research and Development
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases